Peptide University · NeoPeptidos
An advanced scientific course on peptide science for healthcare specialists: biochemistry, pharmacology (PK/PD), therapeutic families, analytical quality, stability and formulation, routes of administration, handling, immunomodulation, clinical safety, critical appraisal of the evidence and monographs of the 20 most relevant peptides. When you pass the final exam you receive a PDF certificate with your name.
Open this module's syllabus on its own page →
A peptide is a polymer of amino acids joined by peptide bonds. It shares its raw material with proteins; the difference is length and, with it, functional specificity.
Each amino acid has an alpha carbon bonded to an amino group (–NH₂), a carboxyl group (–COOH), a hydrogen and a variable side chain (R group). The 20 proteinogenic amino acids are classified by the nature of their R group: nonpolar/hydrophobic (Ala, Val, Leu, Ile, Phe), polar uncharged (Ser, Thr, Asn, Gln), acidic (Asp, Glu), basic (Lys, Arg, His) and special cases (Gly, Pro, Cys). This side-chain chemistry governs folding and interaction with receptors.
In solution, an amino acid exists as a zwitterion: the protonated amino group (–NH₃⁺) and the deprotonated carboxyl group (–COO⁻) coexist. The ionization state depends on pH and on the pKa values of each group. The isoelectric point (pI) is the pH at which the molecule has zero net charge; it is a critical property in peptides because it determines their solubility (minimal near the pI), their behavior in ion-exchange chromatography and their stability in formulation. A peptide rich in basic residues will have a high pI; one rich in acidic residues, a low pI.
The carboxyl of one residue reacts with the amino group of the next in a condensation that releases water and forms an amide bond. That bond has partial double-bond character: it is planar and rigid, with restricted rotation, which defines the dihedral angles (phi/psi) on which the entire three-dimensional structure is built. By convention the chain is read from N-terminus to C-terminus.
Biological activity emerges from conformation, which is described in hierarchical levels:
SAR is the framework that connects structural changes with changes in activity, and it is the basis of analog design. Key principles:
A single substitution can transform the molecule: turn a ligand with a half-life of minutes into a drug with a half-life of days, or an agonist into an antagonist. In peptides, the sequence is not a detail: it is the molecule.
Peptides are classified by several simultaneous criteria:
The dominant technique is Merrifield's SPPS (Nobel 1984). The first amino acid is anchored to a resin; the chain grows through cycles of deprotection → coupling → washing, one residue at a time, from the C-terminus to the N-terminus. Two protection chemistries are used: Fmoc (base-labile, the current standard) and Boc (acid-labile, historical). At the end, the peptide is cleaved from the resin, purified by preparative HPLC and its identity confirmed by mass spectrometry.
The great advantage over biological extraction is reproducibility: exactly the same sequence is obtained batch after batch, with characterizable impurities (deletion, truncated and epimerized peptides) that the analytics of Module 7 can quantify.
Almost no peptide of pharmacological interest is an untouched natural sequence. Between the endogenous peptide and the analog being studied there is a set of chemical modifications with a specific purpose: resisting enzymes, locking in the active conformation or changing the pharmacokinetics.
When you read a sequence with symbols such as Ac-, -NH₂, D-, Aib or a cyclization subscript, they are not decorations: each one explains why that analog lasts longer, degrades less or binds better than the natural peptide it comes from.
Each modification changes the theoretical molecular mass. A mass spectrometry COA must match the mass of the modified analog, not that of the natural sequence: a C-terminal amide, for example, reduces the mass by ~1 Da relative to the free acid, and that difference is detectable.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Pharmacodynamics describes the drug's action on the body. In peptides, almost all activity arises from binding to a receptor with a site complementary to the molecule.
Many peptide receptors are G protein-coupled receptors (GPCR). When activated, the G protein mobilizes second messengers —cyclic AMP (cAMP) via adenylate cyclase, or calcium/IP₃ via phospholipase C— that amplify the signal and start cellular responses. Other peptides act on receptors with tyrosine kinase activity (e.g., the insulin/IGF-1 pathway).
An agonist activates the receptor; an antagonist blocks it without activating it; a partial agonist produces a submaximal response. An advanced concept is biased agonism: a ligand can preferentially activate one signaling pathway (e.g., G protein) over another (β-arrestin) from the same receptor, which allows therapeutic effects to be separated from adverse ones. Dual and triple agonists (Module 3) take this logic to the extreme: a single molecule designed to activate two or three different receptors in a balanced way.
Pharmacokinetics describes what the body does to the drug through the ADME cycle.
The concentration-time curve is summarized by: Cmax (maximum concentration), Tmax (time to Cmax), AUC (area under the curve, total exposure), clearance (CL) (volume cleared per unit of time) and half-life (t½) (time to halve the concentration). The t½ determines the dosing frequency and the time to steady state (~4-5 half-lives).
Native GLP-1 has a t½ of ~1-2 min because of DPP-4. Semaglutide reaches ~1 week. That jump is no accident: it is the direct result of the molecular modifications described below.
Prolonging a peptide's t½ is an exercise in molecular design. Main strategies:
The sermorelin → CJC-1295 pair illustrates the principle: both are GHRH analogs, but CJC-1295 incorporates substitutions that resist DPP-4 (and, in its DAC version, albumin binding), multiplying its duration of action. The pharmacokinetic lesson is constant: small sequence changes yield large changes in behavior, and those changes directly determine the dosing schedule.
Most peptides of interest act on G protein-coupled receptors (GPCR). Understanding what happens to the receptor after activation explains phenomena seen in the literature: loss of response with continuous exposure, differences between pulses and sustained exposure, and why the administration pattern matters as much as the dose.
The activated receptor changes conformation and activates a heterotrimeric G protein. The most common pathways are Gs (↑ cAMP, typical of GLP-1R and GHRH-R), Gq (↑ intracellular Ca²⁺, typical of GHS-R1a and the oxytocin receptor) and Gi (↓ cAMP).
Specific kinases (GRK) phosphorylate the activated receptor.
It uncouples the receptor from the G protein: the signal fades within minutes.
The receptor is removed from the membrane in vesicles.
It returns to the surface (resensitization) or is degraded (downregulation).
Continuous exposure to an agonist favors downregulation; pulsatile exposure allows time for recycling. The classic example is GnRH: in pulses it stimulates the reproductive axis and with continuous exposure it suppresses it, a principle used clinically with depot GnRH agonists. In the somatotropic axis, GH release is physiologically pulsatile, and that is one of the reasons why short-acting and long-acting analogs behave differently.
More exposure does not always mean more effect. For many GPCRs, the rhythm at which the agonist arrives determines whether the response is sustained or switches off.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Incretins are gut hormones released in response to food intake that amplify the metabolic response to nutrients. The main ones are GLP-1 (L cells, ileum and colon) and GIP (K cells, duodenum).
The founding phenomenon is the incretin effect: oral glucose induces a much greater insulin response than the same glucose given intravenously, because the gut, on detecting nutrients, releases incretins that prime the pancreas.
GIP shares the glucose-dependent insulin potentiation and adds effects on adipose tissue and, according to emerging evidence, on central nausea and satiety signaling. The half-life of native GLP-1 is minutes because of DPP-4; the whole class solves that limit with the modifications of Module 2.
The class is organized by the number of co-activated receptors:
Semaglutide and liraglutide: acylated analogs resistant to DPP-4. Semaglutide, given weekly, is the archetype of the class.
Tirzepatide: a single molecule that co-activates both incretin receptors. In studies, co-activation produces a greater metabolic effect than GLP-1 agonism alone.
Retatrutide: adds the glucagon receptor, which increases energy expenditure and hepatic lipid mobilization on top of the incretin effect.
The class is complemented by cagrilintide (an amylin analog, satiety through an independent pathway, often combined with semaglutide) and mazdutide and survodutide (dual GLP-1/glucagon). The weight-loss mechanism combines reduced intake (central satiety + gastric slowing) and, in glucagon agonists, increased energy expenditure.
The strength of this class rests on large clinical trial programs, whose names are worth recognizing:
| Compound | Receptors | Reported differentiating trait |
|---|---|---|
| Semaglutide | GLP-1 | Weekly reference; favorable cardiovascular signal |
| Tirzepatide | GIP + GLP-1 | Greater metabolic magnitude than GLP-1 alone |
| Retatrutide | GLP-1 + GIP + glucagon | Energy expenditure component; early-phase data |
| Cagrilintide | Amylin | Complementary satiety; synergy with GLP-1 |
The conceptual axis for the professional: more co-activated targets mobilize more metabolic levers, at the cost of more complex pharmacology. The most frequent events of the class are gastrointestinal (nausea, early satiety), consistent with gastric slowing and typically dependent on the titration speed — a point taken up again in the safety Module.
The incretin system is not the only hormonal satiety pathway. Amylin, co-secreted with insulin by the β cell, acts through a different circuit, and its combination with GLP-1 is one of the most active lines of metabolic research.
Native human amylin tends to aggregate (it forms amyloid fibrils), so its pharmacological use requires stabilized analogs. Cagrilintide is a long-acting acylated analog; its fixed combination with semaglutide (CagriSema) is studied because it adds two complementary satiety pathways.
An ingested peptide faces gastric pH, proteases and minimal intestinal absorption. Oral semaglutide is the notable exception: it is co-formulated with an absorption enhancer (SNAC) that locally raises pH and facilitates passage through the gastric mucosa. Even so, its oral bioavailability is very low (on the order of 1%), which requires much higher doses than by the subcutaneous route and strict fasting conditions when taking it.
A parallel line seeks small molecules that activate GLP-1R without being peptides (for example, orforglipron, with a recent clinical program). They require neither injection nor absorption enhancers, but their pharmacology —binding to different sites of the receptor, signaling bias profile— is not interchangeable with that of peptide analogs.
| Approach | Advantage | Limitation |
|---|---|---|
| Weekly injectable peptide | High, stable bioavailability | Requires injection |
| Oral peptide with SNAC | No injection | Bioavailability ~1%, strict fasting intake |
| Non-peptide small molecule | Oral and without absorption restrictions | Different pharmacology; more recent clinical program |
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
BPC-157 ("Body Protection Compound") is a 15-amino-acid pentadecapeptide derived from a partial sequence of a protein in gastric juice. It is intensively investigated in soft tissue repair models.
The mechanisms proposed in the preclinical literature include:
A distinctive pharmaceutical trait is its relative stability in gastric medium, uncommon among peptides, which sets it apart from most in terms of study routes. It is important to frame the evidence: it is mostly preclinical, and its translation to humans is an active area of research.
Thymosin β4 is a small, ubiquitous protein whose main functional domain is G-actin binding: it sequesters actin monomers and regulates cytoskeletal dynamics, essential for cell migration. TB-500 is a synthetic fragment that reproduces the active actin-binding domain. The lines of research are the migration of progenitor cells toward the damaged area, angiogenesis and repair, including cardiac tissue models.
GHK-Cu (glycyl-L-histidyl-L-lysine complexed with copper) is a tripeptide with high affinity for the copper(II) ion. Its research interest lies in:
These peptides do not "build" tissue by themselves: they act as signals that orchestrate cell migration, blood supply and matrix remodeling. Understanding them as signaling modulators —not as building material— is key to interpreting the literature correctly.
KPV is a tripeptide (lysine-proline-valine) corresponding to the C-terminus of the hormone alpha-MSH. It is investigated for its relationship with anti-inflammatory pathways, including modulation of NF-κB, with interest in models of mucosal inflammation.
The logic of combinations (for example, BPC-157 with TB-500) rests on complementary mechanisms: one oriented to local repair signaling and angiogenesis, the other to cell motility and progenitor migration. In dermal applications, GLOW-type formulations combine repair peptides with aesthetically focused components.
For the professional, the critical point is to rigorously distinguish the preclinical finding from the clinical data. For several of these compounds, controlled human evidence is limited; interpreting it with judgment —recognizing both the mechanistic potential and the translational uncertainty— is an essential part of the competence this certification aims to develop.
Tissue repair is not an event but a sequence of overlapping phases. Placing each peptide in that sequence is the best way to interpret what each study measures and why certain compounds are investigated in combination.
Platelet aggregation and fibrin clot. Platelets release growth factors (PDGF, TGF-β, VEGF) that set everything else in motion.
Neutrophils arrive, followed by macrophages, which clear debris and shift from a pro-inflammatory (M1) to a reparative (M2) profile.
Angiogenesis, migration of fibroblasts and epithelial cells, deposition of provisional matrix (type III collagen).
Collagen III is replaced by collagen I, fibers reorganize and tissue strength increases progressively.
| Peptide | Phase where its literature concentrates | Described mechanism |
|---|---|---|
| BPC-157 | Proliferation (angiogenesis) | VEGFR2 and nitric oxide signaling; fibroblast migration |
| TB-500 / Tβ4 | Proliferation (migration) | G-actin sequestration and cell motility |
| GHK-Cu | Remodeling | Collagen and elastin synthesis; metalloproteinase modulation |
| KPV | Inflammation | Attenuation of NF-κB and pro-inflammatory cytokines |
Read this way, the logic of the blends (BPC-157 + TB-500, GLOW, KLOW) becomes clear: each component targets a different phase. But design logic is not evidence of effect: the literature describes each peptide separately and there are no controlled studies of the combinations.
Tendon and ligament are poorly vascularized and have low cellularity, so they repair slowly and with tissue of lower quality than the original. That is why many repair models focus on them: they are the setting where an angiogenic or migratory stimulus would have the most room to show differences.
Faster closure in an animal model does not equal better-quality tissue. The most informative studies also measure biomechanical strength and histology of the repaired tissue, not just closure time.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Growth hormone (GH) is secreted by the anterior pituitary under dual hypothalamic control: GHRH stimulates it and somatostatin restrains it. A third axis, ghrelin (from the stomach), enhances release through the growth hormone secretagogue receptor GHS-R.
A decisive physiological trait is pulsatility: GH is not released constantly but in pulses, predominantly at night. That pulsatile nature matters because physiological signaling and feedback mechanisms depend on the pattern, not just the total amount.
GH acts partly directly and partly through IGF-1 (insulin-like growth factor 1), produced mainly in the liver, which mediates many of its anabolic effects and serves as an integrating biomarker of the axis's activity.
A secretagogue is neither GH nor IGF-1: it is a molecule that stimulates the pituitary itself to modulate its natural release. This preserves —at least partially— pulsatility and physiological feedback, unlike administering the exogenous hormone directly.
GHRH analogs act on the GHRH receptor in the pituitary, mimicking the stimulatory hypothalamic signal. They differ mainly in their pharmacokinetics:
Choosing a GHRH analog revolves around a pharmacokinetic trade-off: longer duration simplifies administration but moves away from the physiological pulsatile pattern; shorter action respects it better but requires greater frequency.
The second class of secretagogues acts on the GHS-R receptor (the ghrelin receptor), through a pathway different from GHRH's:
The pharmacological reason for combining a GHRH analog with a GHRP is that they operate through complementary pathways: GHRH "pushes" the positive stimulus while the GHRP, besides activating GHS-R, attenuates the somatostatin brake. The result is a GH pulse greater than the sum of each one separately — a rational, mechanism-based synergy. The CJC-1295 + ipamorelin combination is the canonical example of this logic.
Most of the anabolic effects attributed to growth hormone are not produced by GH directly but by IGF-1, synthesized mainly in the liver under GH stimulation. Understanding IGF-1 is understanding half of the somatotropic axis.
It is a variant with a 13-amino-acid extension at the N-terminus and a Glu to Arg substitution at position 3. The result is a greatly reduced affinity for IGFBPs: a larger free fraction and a half-life much longer than native IGF-1's. That same property means its activity is not «buffered» by the binding protein system.
It is an alternative splicing product of the IGF-1 gene (the IGF-1Ec variant in humans) expressed in muscle after mechanical stimulus. The peptide studied corresponds to its C-terminus (E peptide). The literature is mostly preclinical with heterogeneous results; its natural half-life is very short, which motivated the PEGylated version.
In clinical practice, serum IGF-1 is the integrated marker of GH activity, because GH is pulsatile and a single measurement says little. Secretagogue studies use it as the primary endpoint for the same reason.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
This family is investigated for its interaction with the central nervous system: neuroprotection, stress modulation, sleep and synaptic plasticity. They are usually short peptides derived from fragments of endogenous molecules.
The cross-cutting pharmacokinetic challenge is the blood-brain barrier. Some of these peptides are studied by the intranasal route, which seeks more direct access to the CNS, avoiding part of first-pass effect and systemic degradation.
The melanocortin system is an excellent example of how different receptor subtypes of the same family mediate different functions. Analogs of melanocyte-stimulating hormone act on melanocortin receptors (MC1R–MC5R):
The pharmacological lesson is subtype selectivity: small sequence differences redirect the molecule from the skin (MC1R) to the CNS (MC4R), completely changing its field of research. GHK-Cu (Module 4) complements this dermal block from the matrix remodeling side.
The newest frontier studies peptides linked to cellular aging:
Outside the strictly peptide category but conceptually adjacent, NAD⁺ and its precursors participate in energy metabolism and sirtuin pathways. The biology of longevity is a young, fast-moving field; the professional value lies in reading its literature —mostly preclinical or early-phase— distinguishing robust physiological signal from premature enthusiasm.
The hypothalamic-pituitary-gonadal (HPG) axis is a textbook example of cascading peptide signaling, and several research compounds act at one of its levels.
Hypothalamic neurons release kisspeptin, which activates KISS1R on GnRH neurons. It is the «switch» that initiates puberty and regulates the axis's pulsatility.
A decapeptide released in pulses toward the pituitary. Pulse frequency favors LH (fast pulses) or FSH (slow pulses).
Pituitary glycoproteins that act on the gonad: LH on sex steroid production, FSH on gamete maturation.
Testosterone, estradiol, progesterone and inhibin restrain the axis at the hypothalamus and pituitary.
| Level | Compound | What it mimics or modulates |
|---|---|---|
| Hypothalamus | Kisspeptin | Stimulates GnRH release |
| Pituitary | GnRH analogs | Stimulation in pulses or suppression with continuous exposure |
| Gonad | hCG | LH-type activity (shares the LH/CG receptor) |
| Gonad | hMG (menotropin) | FSH + LH activity |
A compound that acts high in the axis (kisspeptin) preserves the body's own feedback and pulsatility; one that acts low (hCG) stimulates the gonad directly and, over time, the negative feedback of the steroid produced can suppress endogenous LH and FSH secretion. It is the same principle that distinguishes a GH secretagogue from exogenous GH.
Oxytocin is a hypothalamic nonapeptide released by the posterior pituitary. Besides its role in childbirth and lactation, its central action on social behavior has motivated an extensive intranasal literature, with heterogeneous results and effects that depend greatly on context and the individual.
In any endocrine axis, the lower a compound acts, the more direct its effect and the more likely it is to suppress the body's own production through feedback.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
An experimental result is only worth as much as the characterization of the material that produced it. Two questions structure quality control: is it what it claims to be? (identity) and how pure is it? (purity).
High-performance liquid chromatography (HPLC), typically reversed-phase (RP-HPLC), is the reference method for purity. The sample is separated according to each component's interaction with a hydrophobic column and a solvent gradient; each species elutes at a characteristic retention time and produces a peak.
A clean chromatogram, with a well-defined dominant peak and minimal related substances, is the first visual evidence of well-made material.
Purity without identity is not enough: you could have 99% of the wrong molecule. Mass spectrometry (MS) confirms identity by measuring molecular weight with high accuracy.
Robust control combines both: MS says what it is (identity, from the mass) and HPLC says how pure it is (purity, from the peak area). A serious COA presents both, each with its graph: the mass spectrum and the chromatogram.
Beyond identity and purity, there are parameters that describe the actual composition of the powder in the vial:
The COA is the document a laboratory issues for a specific batch. A complete COA includes: compound name and sequence, batch number and date of analysis, HPLC purity result with its chromatogram, MS mass confirmation with its spectrum, peptide content, water and appearance. The operational key is batch traceability: without a batch number and date, a COA cannot be verified as corresponding to the material in your hand.
Every NeoPeptidos compound comes with its batch COA with an HPLC chromatogram and mass confirmation. Being able to audit the identity, purity and content of the material is a requirement of any reproducible research.
A purity of 99% means up to 1% of the chromatogram area corresponds to something else. Knowing what that «something else» usually is lets you read a COA with judgment and understand why two batches with the same purity may not be equivalent.
Solid-phase synthesis adds one amino acid per cycle; no cycle has a 100% yield. Typical impurities are:
HPLC coupled to mass spectrometry (LC-MS) is the reference tool: HPLC separates and quantifies each peak, and MS assigns a mass to each one, which shows whether an impurity is a deletion (lower mass by a specific residue), an oxidation (+16) or a deamidation (+1).
Peptides are purified and isolated as salts. Trifluoroacetic acid (TFA) is the usual counterion after HPLC purification; acetate is obtained with an additional exchange step. The counterion is part of the powder's mass but not of the active peptide, and therefore:
A complete COA shows the chromatogram (not just a percentage), the observed versus theoretical mass, the batch number, the date and the issuing laboratory. A percentage without a chromatogram does not show how many impurities there are or how the peaks were integrated.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
The route of administration determines what fraction of the peptide reaches its target intact. Each route has its own pharmacokinetic logic.
The general rule: the more "convenient" the route (oral, topical), the greater the bioavailability challenge; the parenteral route solves it by delivering the molecule intact.
Most peptides come lyophilized (dehydrated by vacuum sublimation) because the dry solid state maximizes their stability. Lyophilization may include cryoprotective excipients (such as mannitol) that give body to the cake and protect the molecule during the process.
Reconstituting means returning the lyophilizate to solution. Choosing the diluent is not trivial:
A peptide's solubility depends on its pI and its balance of residues. A peptide that tends to aggregate or precipitate near physiological pH may require a specific diluent. Checking that the solution is clear after reconstitution is the practical test of correct dissolution.
For the specialist, knowing subcutaneous technique is part of professional competence. Key elements, presented as technical fundamentals:
These fundamentals are presented as the technical basis of pharmaceutics. Their specific application to a person always belongs to the judgment of the responsible professional and the protocols of their institution.
The subcutaneous route dominates for a reason: it delivers the molecule intact. But there are compounds whose literature was built on other routes, and each one has its own rules.
It is the most difficult route for a peptide: acidic pH, gastric and pancreatic proteases, and an intestinal epithelium that barely lets large, hydrophilic molecules through. It only works with special strategies:
The skin is a barrier designed to let nothing through. The stratum corneum limits penetration to small, lipophilic molecules, and most peptides are neither. That is why cosmetic peptides that work on the skin (GHK-Cu, signaling peptides, SNAP-8) are usually short, sometimes modified with lipophilic chains (palmitoylation) to improve penetration, and act in superficial layers.
| Route | Typical bioavailability | Use in the literature |
|---|---|---|
| Subcutaneous | High | Most systemic peptides |
| Intranasal | Variable, low to moderate | Neuromodulators, oxytocin |
| Oral | Very low, with exceptions | Semaglutide with SNAC; BPC-157 studies in animals |
| Topical | Local, minimal systemic | Cosmetic peptides |
Evidence obtained by one route does not automatically transfer to another. Exposure, target organ and effect profile change with the route; that is why the FDA evaluated topical and injectable use of GHK-Cu separately.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Reconstitution returns the lyophilizate to a liquid state. The procedure respects both the fragility of the molecule and the sterility of the preparation.
Let the lyophilized vial reach room temperature before opening it, to prevent condensation from introducing moisture.
Inject the diluent by letting it run slowly down the inner wall of the vial, never as a direct stream onto the powder cake; the mechanical impact can degrade the molecule.
Swirl the vial gently, without shaking. Vigorous shaking creates foam and can denature the peptide. The solution should be clear.
Store refrigerated and label with the compound, concentration and reconstitution date.
Aseptic technique —disinfecting the stopper, not touching sterile surfaces, using clean materials— is non-negotiable: the preservative in bacteriostatic water limits, but does not eliminate, the risk of contamination.
Concentration calculation is simple arithmetic, but an error here invalidates all later work. The basic relationship is:
Concentration = peptide mass ÷ diluent volume.
Reconstituting a 5 mg vial with 2 mL gives 5 ÷ 2 = 2.5 mg/mL (= 2500 mcg/mL).
The step that generates the most errors is translating a target amount into a volume to draw, because of the change of units: 1 mg = 1000 mcg. With the solution above (2500 mcg/mL), a target amount of 250 mcg requires: 250 ÷ 2500 = 0.1 mL.
On insulin syringes, volume is read in "units": a U-100 syringe has 100 units per mL, so 0.1 mL = 10 units. Moving comfortably between mg, mcg, mL and units is a basic technical skill; above all, it helps you spot an absurd result before it turns into a real error.
NeoPeptidos includes a reconstitution calculator with an mg/mcg selector that automates the calculation. Mastering the underlying arithmetic lets you verify that the tool —and you— are not making mistakes.
The error that ruins the most peptides is not a one-off but cumulative storage. Three enemies: temperature, light and freeze-thaw cycles.
| State | Storage | Approximate stability |
|---|---|---|
| Lyophilized (sealed, long term) | Freezer -20 °C, protected from light | Months to years |
| Lyophilized (short term / transit) | Room temperature, dry and dark | Weeks to months (the powder is stable) |
| Reconstituted | Refrigerator 2-8 °C, not frozen | Days to a few weeks depending on the compound |
Critical points: (1) the lyophilizate is remarkably stable — shipping at room temperature does not compromise it, because the dry powder tolerates weeks or months; (2) once reconstituted it is not frozen, because ice crystals damage the molecule; (3) each freeze-thaw cycle degrades the material somewhat, so it is advisable to aliquot before freezing and thaw only what is needed.
Cold, dry and dark. Aliquot to avoid repeated cycles. Always label with compound, concentration and date: an unlabeled vial is a lost vial. The full storage guide details specific cases.
Reconstitution arithmetic is simple, but most errors happen in three places: mixing up units, miscalculating blends and misreading the syringe. These cases cover all three.
A 10 mg vial reconstituted with 2 mL gives 5 mg/mL = 5,000 mcg/mL. To draw 250 mcg: 250 ÷ 5,000 = 0.05 mL = 5 units on a U-100 syringe.
The same vial with 4 mL gives 2,500 mcg/mL. The same 250 mcg are now 0.1 mL = 10 units. The amount of peptide did not change; it just became easier to measure because the mark is further from zero.
A 70 mg GLOW vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg, 5:1:1 ratio) reconstituted with 3.5 mL has 20 mg/mL of blend. Each 0.1 mL (10 units) contains 2 mg of blend, of which:
In a blend you cannot adjust one component without moving the others: they all go up and down together.
If the target amount falls below 2 units (hard to measure precisely), an intermediate dilution can be prepared: take a known volume of the stock solution and bring it to a larger volume in another sterile vial. The concentration is divided by the dilution factor. The new concentration is always labeled.
| Error | Consequence | How to avoid it |
|---|---|---|
| Confusing mg with mcg | A 1,000-fold error | Always write the unit at every step |
| Confusing mL with units | A 100-fold error | Remember: 1 U-100 unit = 0.01 mL |
| Forgetting the volume of water added | Unknown concentration | Label the date and concentration when reconstituting |
| Treating a blend as a single compound | Wrong amounts per component | Calculate each component by its proportion |
Before drawing, redo the calculation backwards: units × 0.01 × concentration should return the target mass. If it does not match, there is a unit error.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Each peptide family has a safety profile consistent with its mechanism. Knowing it makes it possible to anticipate, contextualize and communicate the expected events.
The safety of a mechanism is predictable from its pharmacodynamics: where there is a potent effect, there are usually off-target effects or physiological consequences of the effect itself. Anticipating them is more useful than reacting to them.
Responsible practice integrates three layers of analysis:
Pharmacokinetics sets the precautions: renal elimination of fragments makes kidney function a variable to consider; the effect of incretins on gastric emptying is relevant in the perioperative context and with other oral therapies. Special populations (pregnancy, extremes of age, relevant comorbidity) require specific caution depending on the compound.
The gastric slowing of incretin agonists can modify the absorption of concomitant oral drugs. Metabolic effects (glucose, insulin sensitivity) can interact with antidiabetic therapies. Evaluating the whole regimen, not the isolated molecule, is part of the analysis.
Each axis suggests its own parameters: blood glucose and weight for metabolic agents; IGF-1 and glucose for GH secretagogues; dermatological monitoring for melanocortins. Monitoring turns an intervention into a measurable, adjustable process.
Professional competence culminates in how everything above is integrated:
Understanding peptide science allows the professional to evaluate the literature with judgment, anticipate safety profiles from the mechanism, recognize deficient material or an exaggerated claim, and make individualized decisions proportionate to the evidence. That informed judgment —not a memorized protocol— is the true goal of this certification.
The labels of approved peptide drugs are the best source for understanding which risks are considered inherent to each class. Although research material is not that drug, class warnings describe the biology of the mechanism.
Compounds whose described mechanism includes stimulation of angiogenesis (for example, via VEGFR2) raise an open question in the presence of undiagnosed neoplasia, because vascularization is a requirement for tumor growth. There are no data showing a risk, but none ruling it out either.
Virtually no research peptide has data in pregnancy. The labels of approved drugs in the metabolic classes recommend stopping them before a planned conception. The absence of data is interpreted as absence of demonstrated safety.
Class contraindications apply to the mechanism, not the brand. If a mechanism carries a warning on its approved drug, the same biology applies when studying any molecule that acts through that pathway.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
A peptide does not «go bad» at random: it degrades through specific chemical reactions that occur at specific residues. Knowing them makes it possible to predict which peptides are fragile and why they are stored the way they are.
Asparagine (Asn) and, to a lesser extent, glutamine (Gln) lose their amide group and become aspartate or glutamate, with a mass increase of ~1 Da and a change in charge. It is especially fast in the Asn-Gly sequence, at neutral or alkaline pH and at elevated temperature. It proceeds through a cyclic intermediate (succinimide) that also produces isoaspartate.
Methionine oxidizes to sulfoxide (+16 Da); tryptophan, histidine and free cysteine are also sensitive. It is favored by dissolved oxygen, light and traces of metals. That is why some analogs replace methionine with norleucine, and why protection from light is not a minor detail.
Aspartate (Asp), especially in the Asp-Gly sequence, can isomerize to isoaspartate through the same succinimide intermediate. The mass does not change, but the structure does, and with it the activity.
The amide bond is stable, but it breaks more easily in acidic medium and, typically, at bonds adjacent to aspartate (Asp-Pro is particularly labile).
The first two residues at the N-terminus can cyclize and split off from the rest of the chain, especially if the second is proline or glycine.
| Reaction | Sensitive residues | Favored by | Mass change |
|---|---|---|---|
| Deamidation | Asn (Asn-Gly), Gln | Neutral/alkaline pH, heat | +1 Da |
| Oxidation | Met, Trp, Cys, His | Oxygen, light, metals | +16 Da |
| Isomerization | Asp (Asp-Gly) | Moderately acidic pH, heat | None |
| Hydrolysis | Bonds next to Asp | Acidic pH, heat | Fragmentation |
Almost all these reactions require water and are accelerated by temperature. That is why a dry, cold peptide lasts years and a peptide in solution at room temperature lasts days.
A peptide can lose activity without any covalent bond breaking: it is enough for its physical state to change.
Molecules associate with each other through their hydrophobic regions. Aggregates can be soluble and invisible or grow into particles and cloudiness. Some peptides (native human amylin is the classic example) form ordered amyloid fibrils. Aggregation:
Shaking a vial creates bubbles: every air-liquid interface is a surface where the peptide partially unfolds and aggregates. That is why the universal instruction to swirl gently and not shake has a precise physical basis.
At low concentrations, an appreciable fraction of the peptide can stick to the glass or plastic of the vial and syringe. It is a real problem with very large dilutions and one of the reasons it is not advisable to prepare extremely dilute solutions.
On freezing, water crystallizes and the peptide becomes concentrated in the liquid channels left between the crystals, together with salts and buffer. That «cryoconcentration» and the associated pH changes favor aggregation. Each cycle adds damage: hence the recommendation to divide into aliquots and not refreeze what has been thawed.
Cloudiness, particles, films or a color change are signs of physical or chemical degradation. A correct solution is clear; if in doubt, it is not used.
Lyophilization is the reason a peptide can travel at room temperature and keep for years. Understanding the process explains what a vial actually contains.
The solution is frozen completely. The peptide is trapped between the ice crystals in an amorphous matrix.
Under vacuum, the ice sublimates: it passes directly from solid to vapor without melting. Most of the water is removed.
At a somewhat higher temperature, the remaining bound water is desorbed, down to a low residual content.
The result is a dry, porous cake that dissolves quickly. Without water, deamidation, isomerization and hydrolysis reactions practically stop.
| Component | Function |
|---|---|
| Mannitol, sucrose, trehalose | Bulking agents and cryo/lyoprotectants: they give structure to the cake and protect the peptide during freezing and drying |
| Buffers (acetate, phosphate, histidine) | They keep the pH in the range where the peptide is most stable |
| Preservatives (benzyl alcohol, m-cresol) | They inhibit microbial growth in multi-dose containers; 0.9% benzyl alcohol is the one in bacteriostatic water |
| Surfactants (polysorbate) | They reduce aggregation at interfaces |
| Counterion (acetate, TFA) | Part of the peptide's salt; it is not active |
Each peptide has a pH range of maximum stability and minimum solubility around its isoelectric point. That is why some compounds reconstitute better in a slightly acidic medium (dilute acetic acid) than in bacteriostatic water: it is not a preference, it is chemistry.
A lyophilized vial is stable; a reconstituted solution starts to degrade from the first minute. Reconstitution should be done close to the time of use and the solution should be refrigerated immediately.
Module assessment
Answer the 5 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Long before antibodies, organisms defended themselves with antimicrobial peptides (AMPs): short, cationic, amphipathic molecules present in skin, mucosa and immune cells.
Because they attack the membrane rather than a specific enzyme, resistance emerges more slowly than with many conventional antibiotics, which makes them interesting as a line of research.
Their activity in the laboratory does not translate easily to systemic use: they are rapidly degraded by proteases, can be toxic at high concentrations and their immunomodulatory effect is double-edged (excess LL-37 has been associated with inflammatory skin diseases such as rosacea and psoriasis).
AMPs are at once antibiotics and immune signals. That dual function explains both the interest in them and the caution with which results are interpreted.
The thymus is the organ where T lymphocytes mature. Its involution with age —it shrinks and is replaced by fat from adolescence onward— is one of the hallmarks of immunosenescence and has motivated the study of thymic peptides.
Despite its name, thymosin β4 is not a thymic hormone in the functional sense: it is a protein that sequesters actin and is found in almost all tissues. Its relevance is tissue repair (repair module), not immunomodulation. Confusing them is a common error in popular literature.
Thymalin is an extract of thymus peptides developed in the Soviet and Russian clinical tradition. The literature, mostly from those groups, describes effects on lymphocyte subpopulations and aging markers. As with the other bioregulators of that school, independent replication is scarce, and the chemical characterization of an extract is inherently less precise than that of a synthetic peptide with a defined sequence.
| Compound | Nature | Main function |
|---|---|---|
| Thymosin α1 | Defined synthetic peptide | Immunomodulation of T lymphocytes |
| Thymosin β4 | Ubiquitous protein | Actin dynamics and repair |
| Thymalin | Peptide extract | Immunomodulation (Russian literature) |
The nervous and immune systems talk to each other through peptides. Several research compounds exploit that conversation to modulate inflammation without suppressing immunity wholesale.
A 28-amino-acid neuropeptide that acts on VPAC1 and VPAC2. It is a vasodilator, bronchodilator and anti-inflammatory: it favors a less inflammatory cytokine profile and the generation of regulatory T lymphocytes. Its plasma half-life is minutes, which limits systemic use and explains the interest in the inhaled or intranasal routes.
Alpha melanocyte-stimulating hormone, besides its role in pigmentation (MC1R), exerts anti-inflammatory effects through melanocortin receptors on immune cells. Its C-terminal tripeptide, KPV, retains much of that anti-inflammatory action without the pigmentary effect, and part of its activity appears to be intracellular, on the NF-κB pathway.
Erythropoietin (EPO) protects tissues through a receptor different from the one that stimulates red blood cell production: a heteromer of the EPO receptor with the common β subunit (CD131), called the innate repair receptor. ARA-290 is an 11-amino-acid peptide derived from helix B of EPO that activates that receptor without an erythropoietic effect. It has been studied in small fiber neuropathy and sarcoidosis.
Selank derives from tuftsin, an immunomodulatory tetrapeptide from IgG. It is studied mainly as an anxiolytic, but it retains part of the immunomodulatory profile of its origin: an example of how a fragment can redirect the function of the parent molecule.
Unlike classic immunosuppressants, these peptides are investigated for rebalancing the inflammatory response. It is an attractive hypothesis, but their evidence in humans is, with exceptions, limited and early-phase.
Module assessment
Answer the 5 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Not all studies are worth the same. Knowing which rung the evidence for a compound is on is the most useful skill in this course, because most of the literature on research peptides sits on the lowest rungs.
Isolated cells or enzymes. Useful for mechanisms; it says nothing about dose, distribution or effect in an organism.
They integrate pharmacokinetics and physiology, but with species differences, per-kilo doses and artificial disease models.
No randomized control group; susceptible to selection bias and the placebo effect.
Control group, randomization and, ideally, double blinding. They are the standard for establishing efficacy.
They integrate several trials; their quality depends on that of the studies included.
| Phase | Main question | Typical size |
|---|---|---|
| Phase 1 | Is it safe? How does it behave in the body? | Dozens of people |
| Phase 2 | Does it have an effect? At what dose? | Hundreds |
| Phase 3 | Does it work against the standard, in a broad population? | Thousands |
| Phase 4 | What happens after approval, in the long term? | Real-world population |
A surrogate endpoint is a marker measured instead of the outcome that really matters: IGF-1 instead of body composition, a laboratory value instead of clinical events. They are useful for deciding whether to keep investigating, but improving a marker does not guarantee improving the outcome. The FDA's review of tesamorelin made this explicit: approving it for visceral fat reduction in a specific population does not validate that endpoint for other conditions.
Before assessing a result, ask: in cells, in animals or in people? With a control group? With which endpoint? The answer completely changes the weight of the claim.
The research peptide literature has recognizable bias patterns. Detecting them does not invalidate a study, but it does adjust how much can be asked of it.
An effective per-kilo dose in a mouse is not equivalent to the same per-kilo dose in a person. Metabolism scales allometrically, roughly with body surface area. That is why regulatory agencies use conversion factors based on body surface area to estimate the human equivalent dose used to set the starting dose of a first-in-human trial, always with an additional safety margin.
That conversion is a clinical trial design tool, not a way to derive doses for use: it does not incorporate the differences in receptors, pharmacokinetics and toxicity between species, which are only known through studies in humans.
Most compounds that work in animal models never go on to demonstrate efficacy in humans. A solid preclinical result is a reason to investigate, not a conclusion about people.
A practical checklist to apply to any article on a peptide, from an abstract in a database to a full trial.
| Question | Why it matters |
|---|---|
| Which compound exactly? | Full peptide or fragment (Tβ4 versus TB-500), salt and source; were its identity and purity verified? |
| In which system? | Cells, animals or people; species and disease model |
| Which route and which exposure? | Evidence from one route does not transfer to another |
| Is there an adequate control group? | Without a control, the effect cannot be attributed |
| How many subjects? | Small samples produce unstable results |
| What is the primary endpoint? | Real outcome or surrogate marker? |
| Is the effect relevant or just significant? | A low p-value says nothing about the size of the effect |
| Was it replicated? | Independent replication is the best test of robustness |
| Who funded it? | Context needed to interpret the design and conclusions |
With a large enough sample, a minimal, irrelevant difference can be «statistically significant». With a small sample, an important effect may not reach significance. What matters is the effect size and its confidence interval: how much the outcome changes and how precisely it was estimated.
A good professional practice is to accompany any claim about a compound with the level of evidence that supports it: «in animal models», «in a phase 2 trial with X participants», «without controlled trials in humans». That precision protects the listener and the credibility of whoever is informing.
The goal of this certification is not to memorize compounds, but to know what is known and what is not about each one. That distinction is what separates scientific information from advertising.
Module assessment
Answer the 5 questions. You can retry as many times as you need.
Resultado
Open this module's syllabus on its own page →
Each monograph summarizes the essentials of a compound in a uniform format. Use them as a quick reference and as an integration of everything studied.
Five compounds that complete the picture of the catalog, in the same quick-reference format.
Module assessment
Answer the 7 questions. You can retry as many times as you need.
Resultado
It unlocks when you pass the assessments of the 14 modules. There are 35 integrative questions; you need 80% to become certified.
Last stage
35 integrative questions · passing threshold 80%
Final exam result
Your certificate with your name is ready. Download it as a PDF and keep it — it includes a unique verifiable reference number.
